© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 3, 252-258,
February 3, 1999
© 1999 Oxford University Press
REPORTS |
Natural History of Dysplasia of the Uterine Cervix
Affiliation of authors: Faculty of Medicine, Department of Public Health Sciences, University of Toronto, Ontario, Canada.
Correspondence to: Philippa Holowaty, Ph.D., Durham Region Health Department, 1615 Dundas St., E., Suite 210, Whitby, Ontario L1N 2L1, Canada (e-mail: holowa_p{at}region.durham.on.ca).
BACKGROUND: A historical cohort of Toronto (Ontario, Canada) women whose Pap smear histories were recorded at a major cytopathology laboratory provided the opportunity to study progression and regression of cervical dysplasia in an era (1962-1980) during which cervical squamous lesions were managed conservatively. METHODS: Actuarial and Cox's survival analyses were used to estimate the rates and relative risks of progression and regression of mild (cervical intraepithelial neoplasia 1 [CIN1]) and moderate (CIN2) dysplasias. In addition, more than 17 000 women with a history of Pap smears between 1970 and 1980 inclusive and who were diagnosed as having mild, moderate, or severe dysplasia were linked to the Ontario Cancer Registry for the outcome of any subsequent cervical cancers occurring through 1989. RESULTS: Both mild and moderate dysplasias were more likely to regress than to progress. The risk of progression from mild to severe dysplasia or worse was only 1% per year, but the risk of progression from moderate dysplasia was 16% within 2 years and 25% within 5 years. Most of the excess risk of cervical cancer for severe and moderate dysplasias occurred within 2 years of the initial dysplastic smear. After 2 years, in comparison with mild dysplasia, the relative risks for progression from severe or moderate dysplasia to cervical cancer in situ or worse was 4.2 (95% confidence interval [CI] = 3.0-5.7) and 2.5 (95% CI = 2.2-3.0), respectively. CONCLUSION: The risk of progression for moderate dysplasia was intermediate between the risks for mild and severe dysplasia; thus, the moderate category may represent a clinically useful distinction. The majority of untreated mild dysplasias were recorded as regressing to yield a normal smear within 2 years.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  TOMBOLA Group Options for managing low grade cervical abnormalities detected at screening: cost effectiveness study BMJ, July 28, 2009; 339(jul28_2): b2549 - b2549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Wheeler, W. C. Hunt, N. E. Joste, C. R. Key, W. G. V. Quint, and P. E. Castle Human Papillomavirus Genotype Distributions: Implications for Vaccination and Cancer Screening in the United States J Natl Cancer Inst, April 1, 2009; 101(7): 475 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Trimble, S. Peng, F. Kos, P. Gravitt, R. Viscidi, E. Sugar, D. Pardoll, and T.C. Wu A Phase I Trial of a Human Papillomavirus DNA Vaccine for HPV16+ Cervical Intraepithelial Neoplasia 2/3 Clin. Cancer Res., January 1, 2009; 15(1): 361 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N K S Wong, F Y Ng, and G Leung Cytological distinction between high-risk and low-risk human papillomavirus infections in SurePath liquid-based cell preparations J. Clin. Pathol., December 1, 2008; 61(12): 1317 - 1322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Howard and A. Lytwyn The HPV vaccine: An analysis of the FUTURE II study Can Fam Physician, December 1, 2007; 53(12): 2157 - 2159. [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Long III, N. N. I. Laack, and B. S. Gostout Prevention, Diagnosis, and Treatment of Cervical Cancer Mayo Clin. Proc., December 1, 2007; 82(12): 1566 - 1574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Van de Velde, M. Brisson, and M.-C. Boily Modeling Human Papillomavirus Vaccine Effectiveness: Quantifying the Impact of Parameter Uncertainty Am. J. Epidemiol., April 1, 2007; 165(7): 762 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vinokurova, N. Wentzensen, J. Einenkel, R. Klaes, C. Ziegert, P. Melsheimer, H. Sartor, L.-C. Horn, M. Hockel, and M. von Knebel Doeberitz Clonal History of Papillomavirus-Induced Dysplasia in the Female Lower Genital Tract J Natl Cancer Inst, December 21, 2005; 97(24): 1816 - 1821. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Blumenthal and L. Gaffikin Cervical Cancer Prevention: Making Programs More Appropriate and Pragmatic JAMA, November 2, 2005; 294(17): 2225 - 2228. [Full Text] [PDF]
|
|
|
|
 |
|
 W. J.M. Hrushesky, R. B. Sothern, W. J. Rietveld, J. Du Quiton, and M. E. Boon Season, Sun, Sex, and Cervical Cancer Cancer Epidemiol. Biomarkers Prev., August 1, 2005; 14(8): 1940 - 1947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Trimble, S. Piantadosi, P. Gravitt, B. Ronnett, E. Pizer, A. Elko, B. Wilgus, W. Yutzy, R. Daniel, K. Shah, et al. Spontaneous Regression of High-Grade Cervical Dysplasia: Effects of Human Papillomavirus Type and HLA Phenotype Clin. Cancer Res., July 1, 2005; 11(13): 4717 - 4723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Clifford, R. K. Rana, S. Franceschi, J. S. Smith, G. Gough, and J. M. Pimenta Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical Cancer Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1157 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. B. Prasad, A. V. Biankin, N. Fukushima, A. Maitra, S. Dhara, A. G. Elkahloun, R. H. Hruban, M. Goggins, and S. D. Leach Gene Expression Profiles in Pancreatic Intraepithelial Neoplasia Reflect the Effects of Hedgehog Signaling on Pancreatic Ductal Epithelial Cells Cancer Res., March 1, 2005; 65(5): 1619 - 1626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Goldie, M. Kohli, D. Grima, M. C. Weinstein, T. C. Wright, F. X. Bosch, and E. Franco Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine J Natl Cancer Inst, April 21, 2004; 96(8): 604 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. F. Schlecht, R. W. Platt, A. Negassa, E. Duarte-Franco, T. E. Rohan, A. Ferenczy, L. L. Villa, and E. L. Franco Modeling the Time Dependence of the Association between Human Papillomavirus Infection and Cervical Cancer Precursor Lesions Am. J. Epidemiol., November 1, 2003; 158(9): 878 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. F. Sawaya, K. J. McConnell, S. L. Kulasingam, H. W. Lawson, K. Kerlikowske, J. Melnikow, N. C. Lee, G. Gildengorin, E. R. Myers, and A. E. Washington Risk of Cervical Cancer Associated with Extending the Interval between Cervical-Cancer Screenings N. Engl. J. Med., October 16, 2003; 349(16): 1501 - 1509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Goodman and D. C. Wilbur Case 32-2003 - A 37-Year-Old Woman with Atypical Squamous Cells on a Papanicolaou Smear N. Engl. J. Med., October 16, 2003; 349(16): 1555 - 1564. [Full Text] [PDF]
|
|
|
|
|
|
N. F. Schlecht, R. W. Platt, E. Duarte-Franco, M. C. Costa, J. P. Sobrinho, J. C. M. Prado, A. Ferenczy, T. E. Rohan, L. L. Villa, and E. L. Franco Human Papillomavirus Infection and Time to Progression and Regression of Cervical Intraepithelial Neoplasia J Natl Cancer Inst, September 3, 2003; 95(17): 1336 - 1343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Weissenborn, A. M. Funke, M. Hellmich, P. Mallmann, P. G. Fuchs, H. J. Pfister, and U. Wieland Oncogenic Human Papillomavirus DNA Loads in Human Immunodeficiency Virus-Positive Women with High-Grade Cervical Lesions Are Strongly Elevated J. Clin. Microbiol., June 1, 2003; 41(6): 2763 - 2767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A E Raffle, B Alden, M Quinn, P J Babb, and M T Brett Outcomes of screening to prevent cancer: analysis of cumulative incidence of cervical abnormality and modelling of cases and deaths prevented BMJ, April 26, 2003; 326(7395): 901 - 901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Burd Human Papillomavirus and Cervical Cancer Clin. Microbiol. Rev., January 1, 2003; 16(1): 1 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Saslow, C. D. Runowicz, D. Solomon, A.-B. Moscicki, R. A. Smith, H. J. Eyre, and C. Cohen American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer CA Cancer J Clin, November 1, 2002; 52(6): 342 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Mandelblatt, W. F. Lawrence, L. Gaffikin, K. K. Limpahayom, P. Lumbiganon, S. Warakamin, J. King, B. Yi, P. Ringers, and P. D. Blumenthal Costs and Benefits of Different Strategies to Screen for Cervical Cancer in Less-Developed Countries J Natl Cancer Inst, October 2, 2002; 94(19): 1469 - 1483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Mandelblatt, W. F. Lawrence, S. M. Womack, D. Jacobson, B. Yi, Y.-t. Hwang, K. Gold, J. Barter, and K. Shah Benefits and Costs of Using HPV Testing to Screen for Cervical Cancer JAMA, May 8, 2002; 287(18): 2372 - 2381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Goldie, L. Kuhn, L. Denny, A. Pollack, and T. C. Wright Policy Analysis of Cervical Cancer Screening Strategies in Low-Resource Settings: Clinical Benefits and Cost-effectiveness JAMA, June 27, 2001; 285(24): 3107 - 3115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Franco, E. Duarte-Franco, and A. Ferenczy Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection Can. Med. Assoc. J., April 1, 2001; 164(7): 1017 - 1025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D Wilson and W. Parsons Cervical cytology smears in sexually transmitted infection clinics in the United Kingdom Sex Transm Inf, April 1, 2001; 77(2): 107 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Virmani, C. Muller, A. Rathi, S. Zoechbauer-Mueller, M. Mathis, and A. F. Gazdar Aberrant Methylation during Cervical Carcinogenesis Clin. Cancer Res., March 1, 2001; 7(3): 584 - 589. [Abstract] [Full Text]
|
|
|
|
|
|
F X Bosch, T Rohan, A Schneider, I Frazer, H Pfister, X Castellsague, S de Sanjose, V Moreno, L M Puig-Tintore, P G Smith, et al. Papillomavirus research update: highlights of the Barcelona HPV 2000 international papillomavirus conference J. Clin. Pathol., March 1, 2001; 54(3): 163 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Lin, E. A. Michalopulos, N. Dhurander, P. C. Cheng, W. Robinson, R. Ashfaq, R. L. Coleman, and C. Y. Muller Allelic Loss and Microsatellite Alterations of Chromosome 3p14.2 Are More Frequent in Recurrent Cervical Dysplasias Clin. Cancer Res., April 1, 2000; 6(4): 1410 - 1414. [Abstract] [Full Text]
|
|
|
|
|
|
I. Nyirjesy Re: Natural History of Dysplasia of the Uterine Cervix J Natl Cancer Inst, August 18, 1999; 91(16): 1420 - 1420. [Full Text] [PDF]
|
|
|
|
|
|
P. Holowaty, A. B. Miller, T. Rohan, and T. To RESPONSE: Re: Natural History of Dysplasia of the Uterine Cervix J Natl Cancer Inst, August 18, 1999; 91(16): 1420a - 1421a. [Full Text]
|
|
|
|
|
|
C. W. Critchlow and N. B. Kiviat Old and New Issues in Cervical Cancer Control J Natl Cancer Inst, February 3, 1999; 91(3): 200 - 201. [Full Text] [PDF]
|
|